Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25916628 | 0.89 | TMPRSS2 (0.32) | TMPRSS2RIPK1 | |
| SCHEMBL25608337 | 0.88 | MGLL (0.38) | MGLLTMPRSS2RIPK1TNK2 | |
| SCHEMBL25916466 | 0.85 | TMPRSS2 (0.32) | TMPRSS2RIPK1 | |
| SCHEMBL30090990 | 0.81 | MGLL (0.35) | MGLLTMPRSS2RIPK1KMT2A | |
| SCHEMBL25916095 | 0.80 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL24312592 | 0.79 | TMPRSS2 (0.46) | MGLLTMPRSS2RIPK1 | |
| SCHEMBL24917025 | 0.79 | RIPK1 (0.34) | MGLLTMPRSS2RIPK1TNK2DOT1L | |
| SCHEMBL25608469 | 0.79 | MGLL (0.39) | MGLLRIPK1TNK2 | |
| SCHEMBL24790995 | 0.77 | TMPRSS2 (0.40) | MGLLTMPRSS2RIPK1KMT2A | |
| SCHEMBL25607729 | 0.77 | TMPRSS2 (0.40) | MGLLTMPRSS2RIPK1DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | MGLL 1174/4885TMPRSS2 100/4885RIPK1 2571/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | MGLL 1174/4885TMPRSS2 100/4885RIPK1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.